Local delivery system of immune modulating drug for unresectable adenocarcinoma: In vitro experimental study and in vivo animal study

CardioVascular and Interventional Radiology

Volumn 29, Issue 5, 2006, Pages 832-837

  Lee, Don Haeng ^a   Kang, Sung Gwon ^b   Jeong, Seok ^a   Yoon, Chang Jin ^b   Choi, Jung Ah ^b   Byun, Ju Nam ^c   Park, Jae Hyung ^b   Lee, Kyu Back ^d  

^a Inha University School of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Chosun University   (South Korea)

^d Korea University College of Medicine   (South Korea)

Author keywords

Adenocarcinoma; Drug delivery; Gastrointestinal tract; OK 432; Sustainable release

Indexed keywords

IMMUNOMODULATING AGENT; MACROGOL; N,N DIMETHYLACETAMIDE; PHOSPHATE BUFFERED SALINE; PICIBANIL; POLYCARBONATE; POLYURETHAN;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGENICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACK; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG STABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HISTOGRAM; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STENT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL RESPONSE MODIFIERS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; GASTROINTESTINAL NEOPLASMS; IMMUNOLOGIC FACTORS; MEMBRANES, ARTIFICIAL; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; PICIBANIL; POLYCARBOXYLATE CEMENT; POLYURETHANES;

EID: 33746425810     PISSN: 01741551     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00270-005-0194-x     Document Type: Article

References (22)

1. Mezawa S, Homma H, Sato T, et al. (2000) A study of carboplatin-coated tube for the unresectable cholangiocarcinoma. Hepatology 32:916-923
2. Uehara K, Ichida T, Sugahara S, et al. (2002) Systemic administration of liposome-encapsulated OK-432 prolongs the survival of rats with hepatocellular carcinoma through the induction of IFN-gamma-producing hepatic lymphocytes. J Gastroenterol Hepatol 17:81-90
3. Okamoto M, Oshikawa T, Tano T, et al. (2003) Involvement of Toll-like receptor 4 signaling in interferon-gamma production and antitumor effect by streptococcal agent OK-432. J Natl Cancer Inst 95:316-326
4. Nose M, Uzawa A, Ogyu T, et al. (2001) OK-432 reduces mortality and bacterial translocation in irradiated and granulocyte-colony stimulating factor (G-CSF)-treated mice. J Radiat Res (Tokyo) 42:191-200
5. Nakahara S, Tsunoda T, Baba T, et al. (2003) Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res 63:4112-4118
6. Takahashi K, Harauchi D, Kimura S, et al. (1998) OK-432 develops CTL and LAK activity in mononuclear cells from regional lymph nodes of lung cancer patients. Int J Immunopharmacol 20:375-388
7. Oshikawa T, Okamoto M, Ohe G, et al. (2003) Anti-tumor immune response induced by the fractions derived from OK-432, a streptococcal preparation, by using a monoclonal antibody TS-2 that neutralizes the interferon-gamma-inducing activity of OK-432: comparison between the TS-2-binding and TS-2-unbinding fraction. Int Immunopharmacol 3:643-655
8. Nishikido M, Kiyohara T, Koga S, et al. (2001) OK-432-induced killer cell activity: potential method for monitoring immunological complications after renal transplantation. Nephrol Dial Transplant 16:2067-2071
9. Itoh T, Ueda Y, Okugawa K, Fujiwara H, et al. (2003) Streptococcal preparation OK-432 promotes functional maturation of human monocyte-derived dendritic cells. Cancer Immunol Immunother 52:207-214
10. Shih CM, Shih CC, Su YY, et al. (2005) In vitro study of drug loading on polymer-free oxide films of metallic implants. J Biomed Mater Res A 75(3):519-529
11. Gershlick AH (2005) Drug eluting stents in 2005. Heart 91(Suppl 3):iii24-iii31
12. Machan L, Burt HM, Hunter WL (1997) Local delivery of chemotherapy: a supplement to existing cancer treatments. A case for surgical pastes and coated stents. Adv Drug Deliv Rev 26:199-207
13. Jung GS, Song HY, Kang SG, et al. (2000) Malignant gastroduodenal obstructions: treatment by means of a covered expandable metallic stent-initial experience. Radiology 216:758-763
14. Monson JR, Donohue JH, McIlrath DC, et al. (1991) Total gastrectomy for advanced cancer. A worthwhile palliative procedure. Cancer 68:1863-1868
15. Meijer S, De Bakker OJ, Hoitsma HF (1983) Palliative resection in gastric cancer. J Surg Oncol 23:77-80
16. Kikuchi S, Tsutsumi O, Kobayashi N, et al. (1999) Does gastrojejunostomy for unresectable cancer of the gastric antrum offer satisfactory palliation?. Hepatogastroenterology 46:584-587
17. Baron TH (2001) Expandable metal stents for the treatment of cancerous obstruction of the gastrointestinal tract. N Engl J Med 344:1681-1687
18. Pinto IT (1997) Malignant gastric and duodenal stenosis: palliation by peroral implantation of a self-expanding metallic stent. Cardiovasc Intervent Radiol 20:431-434
19. Feretis C, Benakis P, Dimopoulos C, et al. (1997) Duodenal obstruction caused by pancreatic head carcinoma: Palliation with self-expandable endoprostheses. Gastrointest Endosc 46:161-165
20. Song HY, Choi KC, Kwon HC, et al. (1992) Esophageal strictures: treatment with a new design of modified Gianturco stent. Work in progress. Radiology 184:729-734
21. Song HY, Yang DH, Kuh JH, et al. (1993) Obstructing cancer of the gastric antrum: palliative treatment with covered metallic stents. Radiology 187:357-358
22. Tatsugami K, Tamada K, Abe K, et al. (2000) Local injections of OK432 can help the infiltration of adoptively transferred CD8+ T cells into the tumor sites and synergistically induce the local production of Th1-type cytokines and CXC3 chemokines. Cancer Immunol Immunother 49:361-368